Introduction
Beta-blockers are a cornerstone in the treatment of patients with heart failure (HF). 1 Large scale trials with carvedilol (US Carvedilol Study 2 and COPERNICUS 3, 4 ), metoprolol (MERIT-HF 5 ), bisoprolol (CIBIS-II 6 ), and nebivolol (SENIORS 7 ) have shown that these drugs reduce morbidity and mortality in HF. As a result, they are now widely used and have received a class IA recommendation in current HF guidelines. 1 Atrial fibrillation is common in HF, and depending on the severity of HF, occurs in up to 30-40% of all patients. 8 The large HF trials that led to the recommendations also included a significant proportion of patients with AF.In current guidelines for HF 1 the recommendation for beta-blockers is not restricted to patients with sinus rhythm, and indeed includes all HF patients, i.e. also those with AF, but it is unknown whether beta-blockers are equally effective and safe in these patients, as they are in those with sinus rhythm.
In patients with sinus rhythm with and without HF, lower heart rate is associated with a better outcome, [9] [10] [11] and reduction of heart rate (by betablockers) probably plays an important role in the beneficial effect of these drugs. In patients with AF, with or without HF, lower heart rate, however, is not associated with a better outcome as was shown recently. 12 Although patients with AF were included in the large HF trials, the absolute number of patients with AF in each individual study was rather limited. [13] [14] [15] [16] The aim of the present meta-analysis was therefore to assess the effect of beta-blockade on outcome (i.e. mortality and hospitalization for HF) in patients with both HF and AF.
Methods

Literature Search
We searched MEDLINE using search tools provided by Pubmed (http://www. ncbi.nlm.nih.gov/pubmed/clinical; used April 1 st 2012) and via OVID. These search tools have been validated by Haynes et al. to optimize retrieval. 17 We also used keywords including atrial fibrillation, heart failure, beta-blocker therapy, beta-blockade, medical therapy and a combination of these, and included papers published in English language. Furthermore, we reviewed reference lists from eligible studies, used the "see related articles" feature for key publications in PubMed, consulted the Cochrane Library, and searched
Summary Background
Beta-blockers are widely used in patients with heart failure (HF) and atrial fibrillation (AF). Recommendation for these drugs in current HF guidelines, however, is based on populations in which the majority had sinus rhythm.
Whether beta-blockers are as useful in atrial fibrillation (AF) is uncertain. We assessed the effect of beta-blockade on outcome in patients with HF and AF.
Methods
For this meta-analysis we used Medline to identify randomised controlled studies. Information about study design, sample characteristics, and outcome (HF hospitalization and mortality) was extracted.
Findings
We identified 4 studies which enrolled 8680 patients with HF and reduced systolic left ventricular function, and 1677 of them had AF (19%; mean age 69 years, 30% women); there were 842 patients treated with beta-blockers, and 835 with placebo. In patients with AF, beta-blockade did not reduce mortality (odds ratio (OR) = 0·86 (0·66-1·13), P = 0·28), while in patients with sinus rhythm there was a significant reduction (OR 0·63 (0·54-0·73), P<0·0001).
There was a significant difference in the effect of beta-blocker therapy in AF versus sinus rhythm (P = 0·046). By meta-regression analysis we did not find confounding by all relevant covariates. When looking at HF hospitalizations in these studies, beta-blocker therapy was not associated with a reduction in patients with AF (OR 1·11 (0·85-1·47), P = 0·44), in contrast to those with sinus rhythm (OR 0.58 [0.49-0.68] P<0.0001) (P = 0·01 for difference in betablocker therapy effect between AF and sinus rhythm).
Interpretation
The effect of beta-blockers on outcome in HF patients who have AF is different than in those who have sinus rhythm. This finding may have implications for the place of these drugs in patients with AF and HF.
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Beta-blockers in heart failure and atrial fibrillation follow-up rates, 10) study design and 11) duration of follow up. Grading was as follows; good quality: eight-11 criteria, fair quality: five-seven criteria and poor quality: < five criteria. 20 
Statistical Analysis
Meta-analysis was performed using a fixed-effects model to determine risk associated with beta-blocker therapy and all-cause mortality, as measured by combined crude mortality rates. In the secondary analysis, heart failure hospitalizations were studied in a similar matter. For comparison with patients in sinus rhythm, subgroup analysis was carried out by testing of heterogeneity across subgroups. Among studies heterogeneity of risk estimates was examined using a standard chi-square test and I 2 statistic for heterogeneity. I 2 is the percentage of variance that is due to between-study variance. Reasons for diversity in study results were explored using meta-regression analysis. 
Role of the funding source
No sponsor of any of the individual trials had any role in the study design, data collection, data interpretation, drafting, or review of the report.
Results
Study search and general characteristics
The search retrieved 248 citations, of whom four fulfilled all criteria as they investigated the randomized treatment allocation of beta-blocker therapy in patients with HF and AF (Figure 1) . All of these studies were specific AF substudies from large HF outcome trials (US-Carvedilol 13 , CIBIS II 14 ,
MERIT-HF 15 , and SENIORS 16 ) that studied the effect of beta-blockers. We were not able to retrieve data from one other large HF beta-blocker study (COPERNICUS), since presence of AF on electrocardiograms at baseline the ISI Web of Knowledge http://scientific.thomson.com/webofknowledge) for publications that cited key publications.
Study Selection
Studies were included which investigated the effect of placebo-controlled, randomized beta-blocker therapy in patients with AF at baseline, and HF with reduced systolic left ventricular ejection fraction (LVEF < 40%). We restricted our final search to beta-blockers that are registered for HF treatment, i.e. metoprolol, carvedilol, bisoprolol, nebivolol. For this reason one large outcome trial which examined bucindolol (BEST) was not included. 18 One study (SENIORS) included both patients with reduced and preserved left ventricular ejection fraction. For the present analysis we only included patients with LVEF < 35%, since this was the cut-off used in that study, both in the methodology in the main study, 7 and in the separate publication of the 2 groups. 19 The subgroup of patients with AF and HF with a preserved ejection fraction are not presented here since beta-blockers are not recommended in these patients. 1 The primary and secondary analysis consisted of secondary analyses Study quality was scored as "good" for all but one, the US-Carvedilol study, which was scored as "fair". All four studies reported the effect on all-cause mortality, and 3 of these 4 also on HF hospitalizations.
The main characteristics of the studies included in the analysis are reported in Beta-blocker therapy in AF patients was not associated with a reduction of HF hospitalisations (14·8% versus 16·2% events), resulting in an OR of 1·11 (0·85 -1·47), P = 0·44) ( Figure 5) . In sinus rhythm patients (8·5% versus 14·3% events), beta-blocker therapy was associated with a reduction of HF hospitalisations (OR 0·58 (0·49 -0·68), P< 0·00001). There was a difference in the effect of beta-blocker therapy in AF versus sinus rhythm (P<0·001).
Discussion
The main finding of the present meta-analysis indicates that the effect of betablockers in patients with HF and AF is significantly different from the effect of these drugs in patients with HF and sinus rhythm. Indeed, beta-blockers were not found to have a favourable effect of HF hospitalizations or mortality in 1677 AF patients who had been enrolled in placebo-controlled, randomized studies.
This finding is important since most patients with HF and AF receive beta-blocker treatment. Beta-blockade is recommended in the current guidelines for HF and AF, albeit for different indications. 1, 22 In the HF guidelines, beta-blockers are recommended for all patients in order to reduce morbidity and mortality, without differentiation regarding rhythm (i.e. sinus rhythm or AF).
As such, these drugs are part of the standard medical therapy for all patients with HF with reduced systolic left ventricular ejection fraction. In addition, beta-blocker therapy has been shown to prevent new-onset or recurrent AF in for beta-blocker therapy (Figure 3) . There was a difference in the effect of beta-blocker therapy in AF versus sinus rhythm (P =0·046). There was no heterogeneity observed among the studies with AF included (I 2 =0%, P= 0·46). We performed meta-regression analysis to determine factors explaining possible confounding. We found no confounding by any of the explored variables. 
CHAPTER 6
Beta-blockers in heart failure and atrial fibrillation
In patients with sinus rhythm, it has been proven that a pronounced reduction in heart rate is associated with improved morbidity and mortality independent of the dose of the used beta-blocker, or by additive therapy with selective If-channel blockade. 9, 10 For patients with permanent AF, it was recently demonstrated, that a more strict rate control was not superior to a lenient rate control. 12 Third, due to loss of the atrial kick and the irregularity in ventricular response during AF, patients with AF may need a higher heart rate to maintain a similar cardiac output, possibly even more so during heart failure. 26 Fourth, a low heart rate in patients with AF may be an expression of an underlying conduction disorder, which may be associated with impaired outcome itself. Finally, AF in patients with HF may be a marker of a poorer hemodynamic situation leading to a worse outcome. 27 In addition to these potential explanations, we also cannot exclude the fact that the present findings could apply to some but not all beta-blockers, 15, 23 after myocardial infarction, 24 and also in a relatively low risk (most hypertension) population. 25 In the AF guidelines, however, beta-blockers are recommended for rate control in order to reduce AF-related symptoms, but not to improve prognosis. 22 In line with the latter study are recent data from the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program, which showed no predictive value of higher heart rates in HF patients with AF, in contrast to the observations in sinus rhythm patients. 11 How can this different effect of beta-blockers between HF patients with AF and sinus rhythm be explained? First, heart rate reduction by betablocker therapy may be less effective in patients with AF than in those with sinus rhythm since the mode of action of beta-blockers is different during AF and sinus rhythm. During sinus rhythm, beta-blockers exert their heart-rate lowering effect by targeting the sinus node, whereas during AF their main site of action is the atrioventricular node. In the present analysis, however, we found a similar mean reduction in heart rate for patients with both AF and sinus rhythm with comparable dosages of beta-blockers. Second, heart rates were only measured at rest. Heart rate reduction during (moderate) exercise may have been different between AF and sinus rhythm patients. Indeed, there may be differences in the optimal heart rate at rest and during exercise, and optimal heart rate reduction by beta-blockers between both groups of patients. 
Conclusion
The present analysis shows that the effect of beta-blockade in HF patients with AF with regard to outcome is different than in HF patients with sinus rhythm. This may affect the place of these drugs in patients with AF and HF.
Clearly, prospective randomized controlled trials in HF specifically aiming at AF patients are warranted to study the prognostic effects of beta-blockers in this population. Figure 5 . Combined HF hospitalisation risk: Effect of beta-blocker therapy in patients with heart failure and atrial fibrillation, and in patients with heart failure and sinus rhythm better effect on outcome than metoprolol. 28 The main COMET study (which compared carvedilol to metoprolol) has been criticized because the dose of the 2 drugs (carvedilol and metoprolol) might not have been equal, since they lowered heart rate to a different extent. However, given the absence of a relation between heart rate lowering and outcome in AF patients, this criticism may be less relevant in this subpopulation of AF patients. Clearly, these betablockers have other properties, and for example carvedilol causes inhibition of apoptosis, antioxidant effects, and free radical scavenging, which may also lead to electrophysiological effect. 29 It must be noted, that carvedilol had a relatively favourable effect in the present analysis in the AF patients in the US Carvedilol study, 13 but these were patients had milder disease than in the other studies, which also may have affected the results. Data on carvedilol in AF in more advanced HF were unfortunately not available (as reported above).
Beta-blockers are standard therapy for HF. Other drugs that are generally recommended for HF are angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers, and aldosterone receptor blockers (or mineralocorticoid anatagonists). It is at least remarkable that all these classes of drugs have been shown to be at least as effective in patients with AF, as they are in patients with sinus rhythm in similar analyses as the present study. 27, 30 
